⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IMRX News
Immuneering Corporation Class A Common Stock
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
globenewswire.com
IMRX
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
globenewswire.com
IMRX
Form 8-K
sec.gov
IMRX
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com
IMRX
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
globenewswire.com
IMRX
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
globenewswire.com
IMRX
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
globenewswire.com
IMRX
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
globenewswire.com
IMRX
Form 8-K
sec.gov
IMRX
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
globenewswire.com
IMRX